What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.
Vedúci predstavitelia priemyslu preskúmajú potenciál umelej inteligencie pri MRI so zvýšeným kontrastom MILÁNO, 21. septembra 2023 /PRNewswire/ — Bracco Imaging SpA., svetový líder v oblasti diagnostického zobrazovania, a Subtle Medical, Inc., popredný inovátor v oblasti získavania…
OAKLAND, Calif., Sept. 21, 2023 /PRNewswire/ — Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND)…
Addition of Kathleen Finnegan, Further Strengthens Kyros’ Established Leadership In Compliance and Substance Use Disorder Innovation MINNEAPOLIS, Sept. 21, 2023 /PRNewswire/ — Today, Kyros, the Minnesota-based technology platform providing substance use disorder (SUD) recovery services,…
Kidney diseases are a leading cause of death in the United States and result primarily from diabetes and high blood pressure. Chronic kidney disease affects an estimated 15 percent of Americans, says the Centers for Disease Control and Prevention (CDC).
Hemodialysis represents one of the most effective treatments for advanced kidney failure for patients whose kidneys can no longer filter wastes, salts, and fluid from the blood. Course director and moderator Jaime Uribarri, MD, Professor of Medicine (Nephrology) at the Icahn School of Medicine at Mount Sinai, directs The Mount Sinai Hospital’s Home Dialysis Program, one of the largest in New York City. He says Icahn Mount Sinai’s Renal Division has been intensively studying and assessing potential therapies to slow progression to end-stage renal disease. While much progress has been made during the past several decades, maintenance of an open vascular access continues to challenge nephrologists today.
Dr. Uribarri credits his colleague Evren Azeloglu, PhD, Associate Professor of Medicine (Nephrology), and Pharmacological Sciences, and a team of researchers for inventing a new implantable vascular access port. “This new port will be a game changer for our patients as it reduces pain and discomfort and allows easy self-cannulation, enabling safe home hemodialysis. We are currently fine-tuning the device and hope to offer this improvement within several years,” says Dr. Uribarri.
In addition to this work, Lili Chan, MD, Associate Professor of Medicine (Nephrology, and General Internal Medicine), at Icahn Mount Sinai, has been focused on an artificial intelligence-driven solution to cull electronic health records. This innovation will help identify unmet social determinants of health commonly associated with adverse clinical outcomes. “This will improve and facilitate surveillance of our patient population in New York City and facilitate the optimization of treatment and symptom management. Furthermore, it underlines a major priority of bringing an equity lens to our care,” says Dr. Uribarri.
Helpful links:
Online registration
A historic review of 75 years of hemodialysis
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the
eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.
Ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 44 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, and gastrointestinal and liver diseases.
Icahn Mount Sinai offers highly competitive MD, PhD, and master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. In addition, more than 535 postdoctoral research fellows are in training within the Health System.
A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into health care products and services that benefit the public.
Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.
The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.
Media Contact
Tildy La Farge, Mount Sinai Health System, 3472139110, [email protected], www.mountsinai.org
SOURCE Mount Sinai Health System
Innerwell’s evidence-based protocols are designed to harness ketamine’s ability to promote neuroplasticity in the brain, acting as a catalyst for healing that can help patients change the way they think, act, and feel. Ketamine is a safe, FDA-approved medication with powerful biological and cognitive effects. Alongside other psychedelics, ketamine has been embraced by mental health clinicians as an alternative to traditional psychiatric medications after a growing body of research has shown that it has rapid, powerful effects on conditions like depression, PTSD, and anxiety.
“We couldn’t be more excited to expand access to our world-class clinical team for patients who are seeking safe and affordable treatment,” said Lisa Kennedy, Innerwell founder and CEO. “We are thrilled to partner with Enthea to help future-thinking employers offer innovative treatments that can have transformative outcomes. With a shared vision to remove barriers to quality care, we are one step closer to providing highly-effective treatment to millions of Americans who suffer from mental health issues.”
Enthea is the only third-party administrator offering medication-assisted therapy as a workplace benefit. Enthea has recently expanded its service to offer nationwide coverage, able to serve employers across the U.S., furthering its mission of providing affordable access to safe and effective ketamine-assisted therapies for all who can benefit.
“Innerwell has one of the most extensive clinical protocols for at-home-ketamine treatment that we’ve seen,” said Sherry Rais, Enthea CEO and co-founder. “We aim to remove health equity obstacles that prevent patients from receiving impactful mental healthcare treatments, and by partnering with Innerwell, we can continue to do so.”
Founded in 2021, Innerwell patients can receive at-home, telehealth care in 14 states, including Arizona, California, Colorado, Connecticut, Florida, New Jersey, New York, Ohio, Oregon, Washington State, and most recently, Texas, Utah, Virginia, and Minnesota, as well as in-person care at six locations across California and New York.
For more information, visit helloinnerwell.com.
About Innerwell:
Innerwell is a revolutionary at-home ketamine therapy platform with an emphasis on therapy. Founded in New York City in 2021, Innerwell is combining the groundbreaking advancements seen in psychedelics with novel approaches to digital care and a focus on creating therapeutic relationships between patients and highly trained, licensed providers. A female-led company, the Innerwell co-founder team consists of CEO Lisa Kennedy, Head of Growth Anthony Mangia, and Medical Director Dr. Michael Cooper. Dr. Cooper holds an M.D. from the Albert Einstein College of Medicine, and he completed psychiatry residency at the NYU School of Medicine, where he served as chief resident and a research therapist on the phase II trial of psilocybin-assisted therapy for alcohol use disorder. For more information, visit www.helloinnerwell.com.
About Enthea
Enthea is a licensed, third-party administrator of health insurance benefits with a mission to provide access to safe, affordable and effective medication-assisted therapies, starting with ketamine therapy. Through Enthea benefit services, companies can cover this new and innovative treatment for their employees and families – leading to improved productivity, increased retention, lower medical costs, and a more engaged workforce. Enthea’s services currently cover ketamine-based treatments and will include MDMA and psilocybin-assisted therapies as they are approved.
Media Contact
Anthony Mangia, Innerwell, 1 (201) 591-3435, [email protected], https://helloinnerwell.com
SOURCE Innerwell
VeloSource is excited to announce a major office move to larger facilities in Des Peres, MO. VeloSource will be moving from its current location in the Cortex in the Central West End to the 5th floor of the Powerscourt Building in the Des Peres area.
ST. LOUIS, Sept. 21, 2023 /PRNewswire-PRWeb/ — VeloSource is excited to announce a major office move to larger facilities in Des Peres, MO. VeloSource will be moving from its current location in the Cortex in the Central West End to the 5th floor of the Powerscourt Building in the Des Peres area.
“We are excited to relocate to our new office in Des Peres,” commented Jeff Schaal, President, and founder.
The new office space is approximately 11,000 square feet, which makes it nearly two times larger than the previous office to accommodate its strategic growth.
“This move represents another significant milestone for our fast-growing healthcare staffing company. The new office space better accommodates our expanding team and enables us to hire additional talent to continue to provide industry-leading support and service to our trusted clients. The additional space will also help drive innovation and provide the opportunity for further expansion into additional markets and service lines,” added Schaal.
The new space reflects the innovative culture of VeloSource and strives to make it a great place to work. The facility features technology-enabled huddle rooms, a training room to assist with both on-site and remote employees, and a world-class conference room where teams can collaborate on solutions with colleagues, customers, partners, and offsite employees.
To showcase the new space, VeloSource will be hosting an Open House on Thursday, October 5 at their new address 12444 Powerscourt Dr., Suite 520, St. Louis, MO 63131 from 3pm to 6pm CST. RSVPs are requested by Wednesday, September 20 at 5pm CST.
About VeloSource (www.VeloSource.com):
VeloSource is a leading healthcare staffing and recruitment agency specializing in Locum Tenens services. By providing a vast network of highly qualified physicians, CRNAs, Physician Assistants, and Nurse Practitioners, VeloSource connects exceptional medical talent with healthcare facilities across the United States ensuring quality patient care and optimal workforce solutions.
Contact:
Mike Gianas
Senior Director of Marketing
VeloSource
Phone: (214) 929-7972
Email: [email protected]
Media Contact
Mike Gianas, VeloSource, 1 2149297972, [email protected], https://www.velosource.com/
SOURCE VeloSource
“Nutrition for preterm infants is guided by two main factors: a baby’s age and weight. Today, technology allows us to measure and compare thousands of gut profiles, which can directly inform how we treat babies during the extremely formative first 1,000 days,” said Astarte Medical Chief Executive Officer Tracy Warren. “This partnership forms the basis of evidence-based precision nutrition care models for clinicians leveraging NICUtrition(R), with the goal to deliver more effective feeding to preterm babies to improve their growth, neurodevelopment and long-term immune health.”
In the U.S., 40% of school-aged children have at least one chronic health condition such as asthma, obesity, or eczema. Tiny Health is pioneering microbiome science for early-stage development, identifying and mitigating health risks before and after birth. The company’s gut test is the first and only test tailored by age that screens for 120,000 bacteria, viruses, fungi and parasites – microbes that can help or harm a premature baby’s development.
“Expecting mothers are searching for greater assurances and a deeper level of clinical guidance for their developing babies. We have created precision technology to determine a baby’s risk for chronic conditions that can influence pediatric nutritional interventions on a case-by-case basis,” said Tiny Health Founder and Chief Executive Officer Cheryl Sew Hoy. “By partnering with Astarte Medical, we’re extending our solution to support infants and families at their most vulnerable time. Our aim is empowering clinicians to incorporate evidence-based gut health protocols to improve outcomes in real-time.”
In a previous multi-center microbiome study, Astarte Medical identified six gut community types among nearly 300 preterm infants born under 34 weeks gestational age. These gut community types, or ‘NutriTypes’, can serve to identify vulnerable infants for adverse events, such as growth faltering or necrotizing enterocolitis, as well as advise on the use of clinical interventions, such as probiotics, micro and macronutrients.
“As survival for preterm infants has improved, meeting a baby’s nutritional needs has become more important and increasingly complex,” said Dr. Nicholas Embleton, Astarte Medical advisor and professor of neonatal medicine at Newcastle University (U.K.). “The interplay of nutrients, microbes and a baby’s immune system is dynamic, yet there is no good method to assess gut health in practice.”
As part of the joint venture, the two companies will share population health data and set up an overlapping workstream between technology teams in order to conduct a proof of concept prospective trial. In addition to re-validating its NICUbiome gut community types using Tiny Health’s pipeline and bioinformatics tools, Astarte Medical will develop a prototype clinical dashboard to deliver AI/ML-based approaches to stratify at-risk infants and deliver targeted interventions. Tiny Health will offer NICU parents the option to test their infants post-discharge to extend the understanding of the maturity patterns of infants born preterm.
About Astarte Medical
Astarte Medical is a clinical intelligence company providing digital solutions to support nutrition and feeding practices and protocol-driven care across pediatric populations. Its first product, NICUtrition® improves growth and clinical outcomes for preterm infants and impacts critical performance metrics for hospitals. Visit astartemedical.com and nicutrition.com for more information.
About Tiny Health
Tiny Health® is the leading microbiome health platform for families, improving health outcomes of future generations through evidence-based insights. Tiny Health’s Gut Health Test is the first-ever at-home gut microbiome test to use next generation sequencing tailored specifically for babies, children, and now adults. For more information, visit tinyhealth.com.
Media Contact
Anthony Stipa, Quickstudy, 1 610-420-1724, [email protected]
SOURCE Astarte Medical
New Board would recognize evolution of cardiology into distinct medical specialty WASHINGTON, Sept. 21, 2023 /PRNewswire/ — Many of the nation’s most prominent cardiovascular organizations, representing tens of thousands of physicians, unite today to pursue the creation of a new Board…
For workouts, having a playlist of inspirational songs and a workout partner will help keep a person motivated. Changing up a workout routine will help keep people engaged with their health journey, and progress should be monitored and rewarded when goals are reached. To inspire nutritious meals, people should try new recipes and focus on wholesome ingredients. Minimizing distractions is important so a person’s focus remains primarily on the health journey.
To learn more about tips for staying motivated on a health journey, please visit Fitness 19 here.
About Fitness 19:
Fitness 19 was founded in 2003 by fitness industry veterans who believed that the traditional health club model wasn’t meeting the needs of most people. They started Fitness 19 to give customers more of what they really want out of a fitness membership. The result is a simple fitness club concept – an extremely affordable, family-friendly facility that offers state-of-the-art cardio, strength, and free weight equipment.
Media Contact
Valerie Cox, Fitness 19, 901-672-7243, [email protected], https://www.fitness19.com
SOURCE Fitness 19
PHILADELPHIA, Sept. 21, 2023 /PRNewswire/ — Today, Lehigh Valley Health Network (LVHN) and its subsidiaries, which include Lehigh Valley Reilly Children’s Hospital, and Children’s Hospital of Philadelphia (CHOP) announced an affiliation agreement that will enhance the care, health…
